EICHORCondition: Heart Failure · Ejection Fraction · Recovery of Function · Sponsor: Chungnam National University Hospital
Interested? Contact the study team ↓
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
This description comes directly from the study's public registry record.
Yujin Yang · 821043311245 · wjsdudtns9@gmail.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * initial echocardiogram ejection fraction less than 40% * follow up echocardiogram ejection fraction over 50% and LVEDD index normal range * NTprobnp criteria 1. eGFR ≥60 ; less 440 2. eGFR 45-59: less 980 3. eGFR 30-44; less 1220 4. eGFR \< 30 : less 5300 5. in HD; no criteria for NTproBNP * on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor) Exclusion Criteria: 1. under age 18 year 2. uncontrolled BP ( over 150/90) 3. coronary revascularization within 6 months 4. significant valve disease 5. arrhythmia requiring rate control 6. CKD with albuminuria ( over 30mg/g) 7. Pregnancy
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Jeonbuk national university hospital | Jeonju, Jeollabuk-do, South Korea | Recruiting |
| Chungnam national university hospital | Daejeon, Republic of Korea, South Korea | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06724653